NIKKEI 225
37,683.97 -776.11 (-2.02%) HANG SENG
17,295.93 +94.66 (+0.55%) CRUDE OIL
82.90 +0.09 (+0.11%) GOLD FUTURES
2,324.90 -13.50 (-0.58%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,583.36 -1,938.40 (-3.62%)
Arecor Therapeutics plc (AREC.L)
| Previous close | 132.50 |
| Open | 0.00 |
| Bid | 130.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 14,030 |
| Market cap | 41.806M |
| Beta (5Y monthly) | -0.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) product with enhanced bioavailability Collaboration focused on overcoming the challenges of oral peptide delivery using a novel lipid technology to provide a more convenient treatment option for patients with diabetes and obesityPote
- GlobeNewswire
First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe
Arecor Therapeutics plc(“Arecor” or the “Group”) FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE First commercial sale triggers milestone payment and future royalties to Arecor Cambridge, UK, 17 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces the triggering of a milestone payment from its global pharmaceutical partner, following the first commercial sale of a prod
- Globe Newswire
Arecor: Business Update
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated during H2 and beyondSignificant progress across proprietary diabetes focused portfolio with AT278 scheduled to complete within Q4 2023Good partner progress across licensed portfolio Cambridge, UK, 20 July 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies
